Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Cancer Clinical Trial

— OPTIMA  

Official title:

Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05337397
• Other study ID #: OPTIMA
• Status: Recruiting
• Start date: May 1, 2022
• Est. completion date: April 1, 2027

Study information

• Verified date: August 2022
• Source: Aarhus University Hospital
• Contact: Jørgen B Jensen, Professor MD
• Phone: +4578452617
• Email: bjerggaard[@]skejby.rm.dk
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Aim: To investigate the feasibility and tolerability of the Olympus Soltive laser in treatment of large recurrent low-grade Ta tumours in an outpatient setting. Background: Non-muscle invasive bladder cancer (NMIBC) is associated with a high yearly recurrence rate up to to 61%. Patients affected are therefore referred to long-term or even life-long follow-up, which burdens both patients and health care system. Recurrent tumours are most frequently treated with TURBT followed by adjuvant intravesical treatment. Repeat TURBT includes a risk of morbidity from the procedure itself and from general anaesthetics, which the procedure requires. Patients with NMIBC are generally elderly, multi-morbid, and as a result, they often show a poor tolerability of general anaesthetics. Thus, the need for non-surgical treatment modalities is imminent and continuous investigations are performed in the field including active surveillance, chemoresection and device-assisted intravesical chemotherapy. Laser ablation is a technique gaining attention in the treatment of NMIBC, based on the prospects of an outpatient treatment modality, which could prove TURBT and general anaesthesia unnecessary in select patients. Methods: The study will be conducted as a prospective feasibility study. Included patients will undergo outpatient laser ablation using the Olympus Soltive laser under local anaesthetics. Patients will be included from Aarhus University Hospital (Denmark), Fundació Puigvert (Spain), Motol University Hospital (Czech Republic) and Institut Universitaire du Cancer Toulouse Oncopole (France). Data will be reported to the eCRF in the online REDCap web application. The eCRF is stored on a secure server under the responsibility of the Department of Clinical medicine at Aarhus University in Denmark. REDCap is a secure web application for building and managing online surveys and databases. The Database will be in agreement with the laws and regulations of the Danish Data Protection Agency and EU regulations (GDPR). The sponsor will be overall responsible for the data entry in the eCRF, and the validity of the data collected at the specific sites. Each participant will be coded with a unique patient identifier to ensure pseudo anonymity. Perspectives: This study will be the first multinational study with focus on feasibility of outpatient laser ablation of large bladder tumours between 1-3 cm. Outpatient laser ablation of these large tumours has the potential to reduce the number of TURBTs per patient, thus easing the life of patients with non-muscle invasive bladder cancer, with fewer surgical procedures as well as reducing the overall treatment related costs for society. If thulium laser ablation proves effective, the treatment modality would be easily implemented and available based on the small size of the machinery.

Description:

The participant will be informed that they can at any time withdraw their consent without influence on their further treatment. Withdrawal can be both with regards to further recordings of data but also deletion of collected data upon request. In case of withdrawal of consent before surgery, the patient will be treated according to local guidelines and excluded from the study. The consent form will be approved by The Regional Committees on Health Research Ethics. The investigators are obligated to ensure, that comprehensive information is provided orally and in writing to the participant. In the case of new relevant information or the design of the study is significantly changed, the participants will be informed, and the consent form updated. Study participants will be informed that a signed consent form grants national investigator approved project staff, direct access to study data and patient's health records. The consent form also allows inspectors from the respective national health authorities access, if requested, in order to allow the authorities to perform controls and checks. Data management: The study will comply with The General Data Protection Regulation and The Data Protection Act. All data are kept confidential in a pseudo anonymized form, according to the GDPR and the Danish Data Protection Agency's guidelines. The investigators, who will code each participant enrolled in the study with a unique patient identification number, will assure this. Information obtained on the participants is confidential and may only be disclosed if permitted by the participant through a signed consent form. The signed consent allows both sponsor, relevant investigators from the study and authorities to enter the patient file. The data generated by the study will be available for inspection upon request by the representatives of the national and local health authorities.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 145
• Est. completion date: April 1, 2027
• Est. primary completion date: April 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least one tumour with a diameter > 1 cm
• Papillary/non-solid tumours
• Previous low-grade NMIBC
• Ability to understand the participant information orally and in writing, in Danish, Spanish, Czech or French respectively
• Signed consent form

Exclusion Criteria:

• Tumour diameter > 3cm
• Tumour in the prostatic urethra
• Previous CIS, high-grade disease or muscle invasive bladder cancer with no later low-grade recurrence
• Positive cytology within 3 months (testing not mandatory in patients with low-grade tumours)
• Pregnancy

Related Conditions & MeSH terms

• Non-Muscle Invasive Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Procedure:
• Laser ablation
Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital	Aarhus

Sponsors (2)

Lead Sponsor	Collaborator
Jørgen Bjerggaard Jensen	University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Succesful laser ablations	The proportion of successful laser ablation outpatient procedures compared to failed procedures leading to standard TURBT	4 months
Secondary	VAS score	Pain during procedure, from 0(no pain) to highest pain(10)	day 0